SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
Envoy Medical, Inc. (COCH) has a negative trailing P/E of -0.5, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. The forward P/E of 1.6 based on analyst estimates suggests a return to profitability is expected. Trailing earnings yield is -182.51%, forward earnings yield 63.69%.
Criteria proven by this page:
- VALUE (100/100, Pass) — analyst target implies upside (+733.3%).
- Forward P/E 1.6 — analysts expect a return to profitability with estimated EPS of $0.46 for FY2028.
- Trailing Earnings Yield -182.51% — negative yield confirms the company is currently unprofitable. Investors are paying for a turnaround rather than current earnings. Forward yield improves to 63.69% as earnings recover.
- Analyst consensus target $6.00 (+733.3% upside) — significant upside potential according to Wall Street analysts.
Overall SharesGrow Score: 34/100 with 2/7 criteria passed.
SharesGrow 7-Criteria Score
✓
VALUE
100/100
Price-to-Earnings & upside
Proven by this page
✗
HEALTH
0/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — COCH
Valuation Multiples
P/E (TTM)-0.5
Forward P/E1.6
PEG RatioN/A
Forward PEGN/A
P/B Ratio-1.11
P/S Ratio57.32
EV/EBITDA-0.5
Per Share Data
EPS (TTM)$-1.21
Forward EPS (Est.)$0.46
Book Value / Share$-0.60
Revenue / Share$0.01
FCF / Share$-0.94
Yields & Fair Value
Earnings Yield-182.51%
Forward Earnings Yield63.69%
Dividend Yield0.00%
Analyst Target$6.00 (+733.3%)
Historical Valuation
| Year |
P/E (TTM) |
PEG Ratio |
P/B Ratio |
P/S Ratio |
Dividend Yield |
| 2020 |
-840,599.1 |
0.00 |
24,250.38 |
0.00 |
- |
| 2021 |
-11.4 |
0.00 |
-2.20 |
319.03 |
- |
| 2022 |
-6.4 |
-0.13 |
-2.81 |
429.30 |
- |
| 2023 |
-0.8 |
-0.01 |
-12.80 |
71.93 |
- |
| 2024 |
-1.3 |
0.03 |
-1.43 |
119.42 |
9.11% |
| 2025 |
-0.5 |
0.03 |
-1.10 |
53.77 |
14.04% |
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2020 |
$0.00 |
$0.00 |
$-701.00 |
- |
| 2021 |
$-1.05 |
$310K |
$-8.68M |
-2798.4% |
| 2022 |
$-1.57 |
$237K |
$-15.92M |
-6718.6% |
| 2023 |
$-2.38 |
$316K |
$-29.92M |
-9469% |
| 2024 |
$-1.49 |
$225K |
$-20.8M |
-9242.2% |
| 2025 |
$-1.23 |
$241K |
$-23.76M |
-9857.3% |
Analyst Estimates
| Year |
EPS (Avg) |
EPS Range |
Revenue (Avg) |
Revenue Range |
Analysts |
| 2026 |
$-0.95 |
$-0.95 – $-0.95 |
$200K |
$200K – $200K |
1 |
| 2027 |
$-0.19 |
$-0.19 – $-0.19 |
$14.4M |
$14.4M – $14.4M |
1 |
| 2028 |
$0.46 |
$0.46 – $0.46 |
$44.3M |
$44.3M – $44.3M |
1 |
| 2029 |
$0.00 |
$0.00 – $0.00 |
$90.4M |
$90.4M – $90.4M |
0 |
